van der Horst-Schrivers ANA, Sluiter WJ, Kruizinga RC, van Leeuwaarde RS, Giles R, Olderode-Berends MJW, Links TP (2019) The incidence of consecutive manifestations in Von Hippel-Lindau disease. Fam Cancer 18:369–376. https://doi.org/10.1007/s10689-019-00131-x

Gossage L, Eisen T, Maher ER (2015) VHL, the story of a tumour suppressor gene. Nat Rev Cancer 15:55–64. https://doi.org/10.1038/nrc3844

Latif F, Tory K, Gnarra J, Yao M, Duh FM, Orcutt ML, Lerman MI (1993) Identification of the von Hippel-Lindau Disease Tumor Suppressor Gene. Science 260(5112):1317–1320. https://doi.org/10.1126/science.8493574

van Leeuwaarde RS, Ahmad S, van Nesselrooij B, et al. Von Hippel-Lindau Syndrome. 2000 May 17 [Updated 2025 May 1]. In: Adam MP, Bick S, Mirzaa GM, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2026. Available from: https://www.ncbi.nlm.nih.gov/books/NBK1463/

Maher ER, Neumann HPH, Richard S (2011) Von Hippel-Lindau disease: a clinical and scientific review. Eur J Hum Genet 19:617–623. https://doi.org/10.1038/ejhg.2010.175

Turturro F (2009) Beyond the Knudson’s hypothesis in von Hippel-Lindau (VHL) disease-proposing vitronectin as a “gene modifier.” J Mol Med 87:591–593. https://doi.org/10.1007/s00109-009-0466-z

Chen F, Kishida T, Yao M, Hustad T, Glavac D, Dean M, Gnarra JR, Lou OM, Duh FM, Glenn G, Green J, Hsia YE, Lamiell J, Li H, Wei MH, Schmidt L, Tory K, Kuzmin I, Stackhouse T, Latif F, Linehan WM, Lerman M, Zbar B (1995) Germline mutations in the von Hippel-Lindau disease tumor suppressor gene: correlations with phenotype. Hum Mutat 5:66–75. https://doi.org/10.1002/humu.1380050109

Maher ER, Webster AR, Richards FM, Green JS, Crossey PA, Payne SJ, Moore AT (1996) Phenotypic expression in von Hippel-Lindau disease: correlations with germline VHL gene mutations. J Med Genet 33:328–332. https://doi.org/10.1136/jmg.33.4.328

Watts D, Gaete D, Rodriguez D, Hoogewijs D, Rauner M, Sormendi S, Wielockx B (2020) Hypoxia pathway proteins are master regulators of erythropoiesis. Int J Mol Sci 21:8131. https://doi.org/10.3390/ijms21218131

Patel SA, Simon MC (2008) Biology of hypoxia-inducible factor-2α in development and disease. Cell Death Differ 15:628–634. https://doi.org/10.1038/cdd.2008.17

Haase VH (2009) The VHL tumor suppressor: master regulator of HIF. Curr Pharm Des 15:3895–3903. https://doi.org/10.2174/138161209789649394

Kaelin WG (2022) Von Hippel-Lindau disease: insights into oxygen sensing, protein degradation, and cancer. J Clin Investig 132:e162480. https://doi.org/10.1172/JCI162480

Rankin EB, Giaccia AJ (2008) The role of hypoxia-inducible factors in tumorigenesis. Cell Death Differ 15:678–685. https://doi.org/10.1038/cdd.2008.21

Zhuang Z, Frerich JM, Huntoon K, Yang C, Merrill MJ, Abdullaev Z, Pack SD, Shively SB, Stamp G, Lonser RR (2014) Tumor derived vasculogenesis in von Hippel-Lindau disease-associated tumors. Sci Rep 4:4102. https://doi.org/10.1038/srep04102

Denko NC (2008) Hypoxia, HIF1 and glucose metabolism in the solid tumour. Nat Rev Cancer 8:705–713. https://doi.org/10.1038/nrc2468

Liberti MV, Locasale JW (2016) The Warburg effect: How does it benefit cancer cells? Trends Biochem Sci 41:211–218. https://doi.org/10.1016/j.tibs.2015.12.001

Chatzopoulos K, Aubry M-C, Gupta S (2022) Immunohistochemical expression of carbonic anhydrase 9, glucose transporter 1, and paired box 8 in von Hippel-Lindau disease–related lesions. Hum Pathol 123:93–101. https://doi.org/10.1016/j.humpath.2022.02.009

Rankin EB, Giaccia AJ (2016) Hypoxic control of metastasis. Science 352(6282):175–180. https://doi.org/10.1126/science.aaf4405

Board PCGE (2021) Von Hippel-Lindau Disease (PDQ®). In: PDQ Cancer Information Summaries [Internet]. National Cancer Institute (US)

Acuña-Pilarte K, Koh MY (2025) The HIF axes in cancer: angiogenesis, metabolism, and immune-modulation. Trends Biochem Sci 50:677–694. https://doi.org/10.1016/j.tibs.2025.06.005

McGettrick AF, O’Neill LAJ (2020) The role of HIF in immunity and inflammation. Cell Metab 32:524–536. https://doi.org/10.1016/j.cmet.2020.08.002

Branco-Price C, Zhang N, Schnelle M, Evans C, Katschinski DM, Liao D, Ellies L, Johnson RS (2012) Endothelial cell HIF-1α and HIF-2α differentially regulate metastatic success. Cancer Cell 21:52–65. https://doi.org/10.1016/j.ccr.2011.11.017

Noguera R, Fredlund E, Piqueras M, Pietras A, Beckman S, Navarro S, Påhlman S (2009) HIF-1α and HIF-2α are differentially regulated in vivo in neuroblastoma: High HIF-1α correlates negatively to advanced clinical stage and tumor vascularization. Clin Cancer Res 15:7130–7136. https://doi.org/10.1158/1078-0432.CCR-09-0223

Ye LY, Zhang Q, Bai XL, Pankaj P, Hu QD, Liang TB (2014) Hypoxia-inducible factor 1α expression and its clinical significance in pancreatic cancer: a meta-analysis. Pancreatology 14:391–397. https://doi.org/10.1016/j.pan.2014.06.008

Hoefflin R, Harlander S, Schäfer S, Metzger P, Kuo F, Schönenberger D, Adlesic M, Peighambari A, Seidel P, Chen C, Consenza-Contreras M, Jud A, Lahrmann B, Grabe N, Heide D, Uhl FM, Chan TA, Duyster J, Zeiser R, Schell C, Heikenwalder M, Schilling O, Hakimi AA, Boerries M, Frew IJ (2020) HIF-1α and HIF-2α differently regulate tumour development and inflammation of clear cell renal cell carcinoma in mice. Nat Commun. https://doi.org/10.1038/s41467-020-17873-3

Sun HX, Xu Y, Yang XR, Wang WM, Bai H, Shi RY, Nayar SK, Devbhandari RP, He YZ, Zhu QF, Sun YF, Hu B, Khan M, Anders RA, Fan J (2013) Hypoxia inducible factor 2 alpha inhibits hepatocellular carcinoma growth through the transcription factor dimerization partner 3/E2F transcription factor 1-dependent apoptotic pathway. Hepatology 57:1088–1097. https://doi.org/10.1002/hep.26188

Holmquist-Mengelbier L, Fredlund E, Löfstedt T, Noguera R, Navarro S, Nilsson H, Pietras A, Vallon-Christersson J, Borg Å, Gradin K, Poellinger L, Påhlman S (2006) Recruitment of HIF-1α and HIF-2α to common target genes is differentially regulated in neuroblastoma: HIF-2α promotes an aggressive phenotype. Cancer Cell 10:413–423. https://doi.org/10.1016/j.ccr.2006.08.026

Qing G, Simon MC (2009) Hypoxia inducible factor-2α: a critical mediator of aggressive tumor phenotypes. Curr Opin Genet Dev 1:60–66. https://doi.org/10.1016/j.gde.2008.12.001

Zhao Y, Xing C, Deng Y, Ye C, Peng H (2024) HIF-1α signaling: essential roles in tumorigenesis and implications in targeted therapies. Genes Dis 11:234–251. https://doi.org/10.1016/j.gendis.2023.02.039

Zhang Q, Lou Y, Zhang J, Fu Q, Wei T, Sun X, Chen Q, Yang J, Bai X, Liang T (2017) Hypoxia-inducible factor-2α promotes tumor progression and has crosstalk with Wnt/β-catenin signaling in pancreatic cancer. Mol Cancer 16:119

Gordan JD, Lal P, Dondeti VR, Letrero R, Parekh KN, Oquendo CE, Greenberg RA, Flaherty KT, Rathmell WK, Keith B, Simon MC, Nathanson KL (2008) HIF-α effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma. Cancer Cell 14:435–446. https://doi.org/10.1016/j.ccr.2008.10.016

Ge J, Hirosue S, Castillon L, Patel SA, Wesolowski L, Dyas A, Yong C, de Haan S, Drost J, Stewart GD, Obenauf AC, Muñoz-Espín D, Vanharanta S (2026) Mechanisms of resistance to VHL loss-induced genetic and pharmacological vulnerabilities. EMBO Mol Med 18:599–619. https://doi.org/10.1038/s44321-025-00361-w

Huang E, Tiburcio P, Choi H (2014) Complex role of HIF in cancer: the known, the unknown, and the unexpected. Hypoxia 18:59–70. https://doi.org/10.2147/hp.s50651

Clifford SC, Cockman ME, Smallwood AC, Mole DR, Woodward ER, Maxwell PH, Ratcliffe PJ, Maher ER (2001) Contrasting effects on HIF-1α regulation by disease-causing pVHL mutations correlate with patterns of tumourigenesis in von Hippel-Lindau disease. Hum Mol Genet 10:1029–1038. https://doi.org/10.1093/hmg/10.10.1029

Hoffman MA, Ohh M, Yang H, Klco JM, Ivan M, Kaelin WG Jr (2001) von Hippel-Lindau protein mutants linked to type 2C VHL disease preserve the ability to downregulate HIF. Human Mol Genetics 10(10):1019–1027. https://doi.org/10.1093/hmg/10.10.1019

Jonasch E, Donskov F, Iliopoulos O, Rathmell WK, Narayan VK, Maughan BL, Oudard S, Else T, Maranchie JK, Welsh SJ, Thamake S, Park EK, Perini RF, Linehan WM, Srinivasan R (2021) Belzutifan for Renal Cell Carcinoma in von Hippel–Lindau Disease. N Engl J Med 385:2036–2046. https://doi.org/10.1056/nejmoa2103425

Ohh M, Yauch RL, Lonergan KM, Whaley JM, Stemmer-Rachamimov AO, Louis DN, Gavin BJ, Kley N, Kaelin WG, Iliopoulos O (1998) The von Hippel-lindau tumor suppressor protein is required for proper assembly of an extracellular fibronectin matrix. Mol Cell 1:959–968. https://doi.org/10.1016/S1097-2765(00)80096-9

Oxburgh L (2022) the extracellular matrix environment of clear cell renal cell carcinoma. Cancers 14:4072. https://doi.org/10.3390/cancers14174072

Article  PubMed  PubMed Central  CAS  Google Scholar 

Stickle NH, Chung J, Klco JM, Hill RP, Kaelin WG, Ohh M (2004) pVHL modification by nedd8 is required for fibronectin matrix assembly and suppression of tumor development. Mol Cell Biol 24:3251–3261. https://doi.org/10.1128/MCB.24.8.3251-3261.2004

Li S, Li W, Yuan J, Bullova P, Wu J, Zhang X, Liu Y, Plescher M, Rodriguez J, Bedoya-Reina OC, Jannig PR, Valente-Silva P, Yu M, Henriksson MA, Zubarev RA, Smed-Sörensen A, Suzuki CK, Ruas JL, Holmberg J, Larsson C, Christofer Juhlin C, von Kriegsheim A, Cao Y, Schlisio S (2022) Impaired oxygen-sensitive regulation of mitochondrial biogenesis within the von Hippel-Lindau syndrome. Nat Metab 4:739–758. https://doi.org/10.1038/s42255-022-00593-x

Zhang H, Gao P, Fukuda R, Kumar G, Krishnamachary B, Zeller KI, Dang CVV, Semenza GL (2007) HIF-1 inhibits mitochondrial biogenesis and cellular respiration in VHL-deficient renal cell carcinoma by repression of C-MYC activity. Cancer Cell 11:407–420. https://doi.org/10.1016/j.ccr.2007.04.001

Meierhofer D, Mayr JA, Foetschl U, Berger A, Fink K, Schmeller N, Hacker GW, Hauser-Kronberger C, Kofler B, Sperl W (2004) Decrease of mitochondrial DNA content and energy metabolism in renal cell carcinoma. Carcinogenesis 25:1005–1010. https://doi.org/10.1093/carcin/bgh104

Favier J, Brière J-J, Burnichon N, Rivière J, Vescovo L, Benit P, Giscos-Douriez I, De Reyniès A, Bertherat J, Badoual C, Tissier F, Amar L, Libé R, Plouin P-F, Jeunemaitre X, Rustin P, Gimenez-Roqueplo A-P (2009) The warburg effect is genetically determined in inherited pheochromocytomas. PLoS ONE 4:e7094. https://doi.org/10.1371/journal.pone.0007094

Unwin RD, Craven RA, Harnden P, Hanrahan S, Totty N, Knowles M, Eardley I, Selby PJ, Banks RE (2003) Proteomic changes in renal cancer and co-ordinate demonstration of both the glycolytic and mitochondrial aspects of the Warburg effect. Proteomics 3:1620–1632. https://doi.org/10.1002/pmic.200300464

Wang Z, Yan M, Ye L, Zhou Q, Duan Y, Jiang H, Wang L, Ouyang Y, Zhang H, Shen Y, Ji G, Chen X, Tian Q, Xiao L, Wu Q, Meng Y, Liu G, Ma L, Lei B, Lu Z, Xu D (2024) VHL suppresses autophagy and tumor growth through PHD1-dependent Beclin1 hydroxylation. EMBO J 43:931–955. https://doi.org/10.1038/s44318-024-00051-2

Debnath J, Gammoh N, Ryan KM (2023) Autophagy and autophagy-related pathways in cancer. Nat Rev Mol Cell Biol 24:560–575. https://doi.org/10.1038/s41580-023-00585-z

van de Kooij B, van der Wal FJ, Rother MB, Wiegant WW, Creixell P, Stout M, Joughin BA, Vornberger J, Altmeyer M, van Vugt MATM, Yaffe MB, van Attikum H (2024) The Fanconi anemia core complex promotes CtIP-dependent end resection to drive homologous recombination at DNA double-strand breaks. Nat Commun 15:7076. https://doi.org/10.1038/s41467-024-51090-6

de Alba EL, Salguero I, Giménez-Llorente D, Montes-Torres J, Fernández-Sanromán Á, Casajús-Pelegay E, Terrón-Bautista J, Barroso-González J, Bernal JA, Macintyre G, Fernández-Leiro R, Losada A, Cortés-Ledesma F (2025) A comprehensive genetic catalog of human double-strand break repair. Science 390:eadr5048. https://doi.org/10.1126/science.adr5048

Metcalf JL, Bradshaw PS, Komosa M, Greer SN, Stephen Meyn M, Ohh M (2014) K63-Ubiquitylation of VHL by SOCS1 mediates DNA double-strand break repair. Oncogene 33:1055–1065. https://doi.org/10.1038/onc.2013.22

Scanlon SE, Hegan DC, Sulkowski PL, Glazer PM (2018) Suppression of homology-dependent DNA double-strand break repair induces PARP inhibitor sensitivity in VHL-deficient human renal cell carcinoma. Oncotarget 9:4647–4660. https://doi.org/10.18632/oncotarget.23470

Li M, Kim WY (2011) Two sides to every story: the HIF-dependent and HIF-independent functions of pVHL. J Cell Mol Med 15:187–195. https://doi.org/10.1111/j.1582-4934.2010.01238.x

Liao C, Hu L, Zhang Q (2024) Von Hippel-Lindau protein signalling in clear cell renal cell carcinoma. Nat Rev Urol 21:662–675. https://doi.org/10.1038/s41585-024-00876-w

Wang Y, Song J, Zheng S, Wang S (2025) Advancements in understanding the molecular mechanisms and clinical implications of Von Hippel-Lindau syndrome: a comprehensive review. Transl Oncol 51:102193. https://doi.org/10.1016/j.tranon.2024.102193

Frew IJ, Moch H (2015) A clearer view of the molecular complexity of clear cell renal cell carcinoma. Annu Rev Pathol 10:263–289. https://doi.org/10.1146/annurev-pathol-012414-040306

Turajlic S, Xu H, Litchfield K, Rowan A, Chambers T, Lopez JI, Nicol D, O’Brien T, Larkin J, Horswell S, Stares M, Au L, Jamal-Hanjani M, Challacombe B, Chandra A, Hazell S, Eichler-Jonsson C, Soultati A, Chowdhury S, Rudman S, Lynch J, Fernando A, Stamp G, Nye E, Jabbar F, Spain L, Lall S, Guarch R, Falzon M, Proctor I, Pickering L, Gore M, Watkins TBK, Ward S, Stewart A, DiNatale R, Becerra MF, Reznik E, Hsieh JJ, Richmond TA, Mayhew GF, Hill SM, McNally CD, Jones C, Rosenbaum H, Stanislaw S, Burgess DL, Alexander NR, Swanton C (2018) tracking cancer evolution reveals constrained routes to metastases: TRACERx renal. Cell 173:581-594.e12. https://doi.org/10.1016/j.cell.2018.03.057

Mitchell TJ, Turajlic S, Rowan A, Nicol D, Farmery JHR, O’Brien T, Martincorena I, Tarpey P, Angelopoulos N, Yates LR, Butler AP, Raine K, Stewart GD, Challacombe B, Fernando A, Lopez JI, Hazell S, Chandra A, Chowdhury S, Rudman S, Soultati A, Stamp G, Fotiadis N, Pickering L, Au L, Spain L, Lynch J, Stares M, Teague J, Maura F, Wedge DC, Horswell S, Chambers T, Litchfield K, Xu H, Stewart A, Elaidi R, Oudard S, McGranahan N, Csabai I, Gore M, Futreal PA, Larkin J, Lynch AG, Szallasi Z, Swanton C, Campbell PJ (2018) Timing the landmark events in the evolution of clear cell renal cell cancer: TRACERx renal. Cell 173:611-623.e17. https://doi.org/10.1016/j.cell.2018.02.020

Crossey PA, Richards FM, Foster K, Green JS, Prowse A, Latif F, Ferguson-Smith MA (1994) Identification of intragenic mutations in the von Hippel-Lindau disease tumour suppressor gene and correlation with disease phenotype. Human Mol Genetics 3(8):1303–1308. https://doi.org/10.1093/hmg/3.8.1303

Ganner A, Ferrara AM, Sekula P, Schiavi F, Joo JH, Sanso G, Almeida MQ, Knoblauch AL, Gizaw CJ, Krzystolik K, Astheimer SC, Achatz MI, Vieites A, Donegan D, Hundsberger T, Lubinski J, Yildirim Simsir I, Bandgar T, Hasse-Lazar K, Pawlaczek A, Zandee W, Yu K, Kater CE, Rostomyan L, Qi X-P, Deutschbein T, Remde H, Dallagnol TN, Yukina M, Baudrand R, Andreescu CE, Kunavisarut T, Ishak ND, Le Guillou HX, Shutler G, Jovanovic M, Pęczkowska M, Calissendorf J, Circosta F, Bugalho MJ, Corssmit EPM, Gimm O, Quinkler M, Goldmann A, Watutantrige Fernando S, Zovato S, Santana LS, Freitas-Castro F, Rothermundt C, Zimmermann J, Durmaz A, Aykut A, Vroonen L, Krauss T, Taschner C, Ruf J, Klingler J-H, Gläsker S, Lang S, Bucher F, Agostini H, Jilg C, Schultze-Seemann W, Bausch B, Bergfeld A, Rhein K, Uslar T, Concistrè A, Juhlin CC, Casali-da-Rocha JC, Petramala L, Tsoy U, Grineva E, Fang X-D, Kotsis F, Schaefer T, Links TP, Makay Ö, Fagundes GFC, Ngeow J, Shah N, Opocher G, Barontini M, Larsson C, Januszewicz A, Viana Lima J, Wohllk N, Letizia C, Donatini G, Maher ER, Beltsevich D, Bancos I, Cybulski C, Walz MK, Köttgen A, Eng C, Neumann HPH, Neumann-Haefelin E (2025) Genotype-specific neoplastic risk profiles in patients with VHL disease. Endocr Relat Cancer 32:e240260. https://doi.org/10.1530/ERC-24-0260

Ong KR, Woodward ER, Killick P, Lim C, Macdonald F, Maher ER (2007) Genotype-phenotype correlations in von Hippel-Lindau disease. Hum Mutat 28:143–149. https://doi.org/10.1002/humu.20385

Mettu P, Agrón E, Samtani S, Chew EY, Wong WT (2010) Genotype-phenotype correlation in ocular von Hippel-Lindau (VHL) disease: the effect of missense mutation position on ocular VHL phenotype. Investig Opthalmol Vis Sci 51:4464. https://doi.org/10.1167/iovs.10-5223

Liu S-J, Wang J-Y, Peng S-H, Li T, Ning X-H, Hong B-A, Liu J-Y, Wu P-J, Zhou B-W, Zhou J-C, Qi N-N, Peng X, Zhang J-F, Ma K-F, Cai L, Gong K (2018) Genotype and phenotype correlation in von Hippel-Lindau disease based on alteration of the HIF-α binding site in VHL protein. Genet Med 20:1266–1273. https://doi.org/10.1038/gim.2017.261

Maranchie JK, Afonso A, Albert PS, Kalyandrug S, Phillips JL, Zhou S, Peterson J, Ghadimi BM, Hurley K, Riss J, Vasselli JR, Ried T, Zbar B, Choyke P, Walther MM, Klausner RD, Linehan WM (2004) Solid renal tumor severity in von Hippel Lindau disease is related to germline deletion length and location. Hum Mutat 23:40–46. https://doi.org/10.1002/humu.10302

Chiorean A, Farncombe KM, Delong S, Andric V, Ansar S, Chan C, Clark K, Danos AM, Gao Y, Giles RH, Goldenberg A, Jani P, Krysiak K, Kujan L, Macpherson S, Maher ER, McCoy LG, Salama Y, Saliba J, Sheta L, Griffith M, Griffith OL, Erdman L, Ramani A, Kim RH (2022) Large scale genotype- and phenotype-driven machine learning in Von Hippel-Lindau disease. Hum Mutat 43:1268–1285. https://doi.org/10.1002/humu.24392

Ciotti P, Garuti A, Gulli R, Ballestrero A, Bellone E, Mandich P (2009) Germline mutations in the von Hippel-Lindau gene in Italian patients. Eur J Med Genet 52:311–314. https://doi.org/10.1016/j.ejmg.2009.05.007

Hes F, van der Luijt R, Janssen A, Zewald R, de Jong G, Lenders J, Links T, Luyten G, Sijmons R, Eussen H, Halley D, Lips C, Pearson P, van den Ouweland A, Majoor-Krakauer D (2007) Frequency of Von Hippel-Lindau germline mutations in classic and non-classic Von Hippel-Lindau disease identified by DNA sequencing, Southern blot analysis and multiplex ligation-dependent probe amplification. Clin Genet 72:122–129. https://doi.org/10.1111/j.1399-0004.2007.00827.x

Vocke CD, Ricketts CJ, O’Brien L, Lebensohn AP, Rathi N, Nielsen D, Gautam R, Pack SD, Raffeld M, Chew EY, Chittiboina P, Malayeri AA, Welch MR, Merino MJ, Srinivasan R, Ball MW, Linehan WM (2026) Multigenerational VHL family characterized by pathogenic germline ELOC variant: Response to belzutifan. Urol Oncol Semin Orig Investig 44:120.e21-120.e27. https://doi.org/10.1016/j.urolonc.2025.10.009

Andreou A, Yngvadottir B, Bassaganyas L, Clark G, Martin E, Whitworth J, Cornish AJ, Houlston RS, Rich P, Egan C, Hodgson SV, Warren AY, Snape K, Maher ER (2022) Elongin C ( ELOC/TCEB1)-associated von Hippel-Lindau disease. Hum Mol Genet 31:2728–2737. https://doi.org/10.1093/hmg/ddac066

Wang JJ, Huang RR, Cone BD, Kang S-HL, Setoodeh R, Sisk AE, Sajed DP, Shuch BM, Sowalsky AG, Ye H (2025) ELOC-mutated renal cell carcinoma is a rare indolent tumor with distinctive genomic characteristics. Mod Pathol 38:100777. https://doi.org/10.1016/j.modpat.2025.100777

Zhuang Z, Yang C, Lorenzo F, Merino M, Fojo T, Kebebew E, Popovic V, Stratakis CA, Prchal JT, Pacak K (2012) Somatic HIF2A gain-of-function mutations in paraganglioma with polycythemia. N Engl J Med 367:922–930. https://doi.org/10.1056/NEJMoa1205119

Santarpia L, Sarlis NJ, Santarpia M, Sherman SI, Trimarchi F, Benvenga S (2007) Mosaicism in von Hippel-Lindau disease: an event important to recognize. J Cell Mol Med 11:1408–1415. https://doi.org/10.1111/j.1582-4934.2007.00122.x

Oldfield LE, Grzybowski J, Grenier S, Chao E, Downs GS, Farncombe KM, Stockley TL, Mete O, Kim RH (2022) VHL mosaicism: the added value of multi-tissue analysis. NPJ Genom Med 7:21. https://doi.org/10.1038/s41525-022-00291-3

Binderup MLM, Smerdel M, Borgwadt L, Beck Nielsen SS, Madsen MG, Møller HU, Kiilgaard JF, Friis-Hansen L, Harbud V, Cortnum S, Owen H, Gimsing S, Friis Juhl HA, Munthe S, Geilswijk M, Rasmussen ÅK, Møldrup U, Graumann O, Donskov F, Grønbæk H, Stausbøl-Grøn B, Schaffalitzky de Muckadell O, Knigge U, Dam G, Wadt KAW, Bøgeskov L, Bagi P, Lund L, Stochholm K, Ousager LB, Sunde L (2022) von Hippel-Lindau disease: updated guideline for diagnosis and surveillance. Eur J Med Genet 65:104538. https://doi.org/10.1016/j.ejmg.2022.104538

Daniels AB, Tirosh A, Huntoon K, Mehta GU, Spiess PE, Friedman DL, Waguespack SG, Kilkelly JE, Rednam S, Pruthi S, Jonasch EA, Baum L, Chahoud J (2023) Guidelines for surveillance of patients with von Hippel-Lindau disease: consensus statement of the international VHL surveillance guidelines consortium and VHL alliance. Cancer 129:2927–2940. https://doi.org/10.1002/cncr.34896

Wittebol-Post D, Hes FJ, Lips CJM (1998) The eye in von Hippel-Lindau disease: long-term follow-up of screening and treatment—recommendations. J Intern Med 243:555–561. https://doi.org/10.1046/j.1365-2796.1998.00338.x

Article  PubMed  CAS  Google Scholar 

Binderup MLM, Budtz-Jørgensen E, Bisgaard ML (2016) Risk of new tumors in von Hippel-Lindau patients depends on age and genotype. Genet Med 18:89–97. https://doi.org/10.1038/gim.2015.44

Wiley HE, Krivosic V, Gaudric A, Gorin MB, Shields C, Shields J, Aronow ME, Chew EY (2019) Management of retinal hemangioblastoma in von hippel-lindau disease. Retina 39:2254–2263. https://doi.org/10.1097/IAE.0000000000002572

Klingler J-H, Gläsker S, Bausch B, Urbach H, Krauss T, Jilg CA, Steiert C, Puzik A, Neumann-Haefelin E, Kotsis F, Agostini H, Neumann HPH, Beck J (2020) Hemangioblastoma and von Hippel-Lindau disease: genetic background, spectrum of disease, and neurosurgical treatment. Child Nerv Syst 36:2537–2552. https://doi.org/10.1007/s00381-020-04712-5

Wind JJ, Lonser RR (2011) Management of von Hippel-Lindau disease-associated CNS lesions. Expert Rev Neurother 11:1433–1441. https://doi.org/10.1586/ern.11.124

Ammerman JM, Lonser RR, Dambrosia J, Butman JA, Oldfield EH (2006) Long-term natural history of hemangioblastomas in patients with von Hippel-Lindau disease: implications for treatment. J Neurosurg 105:248–255. https://doi.org/10.3171/jns.2006.105.2.248

Bausch B, Jilg C, Gläsker S, Vortmeyer A, Lützen N, Anton A, Eng C, Neumann HPH (2013) Renal cancer in von Hippel-Lindau disease and related syndromes. Nat Rev Nephrol 9:529–538. https://doi.org/10.1038/nrneph.2013.144

Cinque A, Minnei R, Floris M, Trevisani F (2022) The clinical and molecular features in the VHL renal cancers: Close or distant relatives with sporadic clear cell renal cell carcinoma? Cancers 14:5352. https://doi.org/10.3390/cancers14215352

Chahoud J, McGettigan M, Parikh N, Boris RS, Iliopoulos O, Rathmell WK, Daniels AB, Jonasch E, Spiess PE (2021) Evaluation, diagnosis and surveillance of renal masses in the setting of VHL disease. World J Urol 39:2409–2415. https://doi.org/10.1007/s00345-020-03441-3

Charlesworth M, Verbeke CS, Falk GA, Walsh M, Smith AM, Morris-Stiff G (2012) Pancreatic lesions in von Hippel-lindau disease? A systematic review and meta-synthesis of the literature. J Gastrointest Surg 16:1422–1428. https://doi.org/10.1007/s11605-012-1847-0

Laks S, van Leeuwaarde R, Patel D, Keutgen XM, Hammel P, Nilubol N, Links TP, Halfdanarson TR, Daniels AB, Tirosh A (2022) Management recommendations for pancreatic manifestations of von Hippel-Lindau disease. Cancer 128:435–446. https://doi.org/10.1002/cncr.33978

Coco D, Leanza S (2024) A Narrative Review of Pheochromocytoma in VHL. J Kidney Cancer VHL 11:19–23. https://doi.org/10.15586/jkcvhl.v11i1.275

Nölting S, Bechmann N, Taieb D, Beuschlein F, Fassnacht M, Kroiss M, Eisenhofer G, Grossman A, Pacak K (2022) Personalized management of pheochromocytoma and paraganglioma. Endocr Rev 43:199–239. https://doi.org/10.1210/endrev/bnab019

Eisenhofer G, Lenders JWM, Linehan WM, Walther MM, Goldstein DS, Keiser HR (1999) Plasma normetanephrine and metanephrine for detecting pheochromocytoma in von Hippel-Lindau disease and multiple endocrine neoplasia type 2. N Engl J Med 340:1872–1879. https://doi.org/10.1056/NEJM199906173402404

Kruizinga RC, Sluiter WJ, De Vries EGE, Zonnenberg BA, Lips CJ, Van Der Horst-Schrivers ANA, Walenkamp AME, Links TP (2014) Calculating optimal surveillance for detection of von Hippel-Lindau-related manifestations. Endocr Relat Cancer 21:63–71. https://doi.org/10.1530/ERC-13-0308

Ilias I, Pacak K (2004) Current approaches and recommended algorithm for the diagnostic localization of pheochromocytoma. J Clin Endocrinol Metab 89:479–491. https://doi.org/10.1210/jc.2003-031091

Ramachandran R, Rewari V (2017) Current perioperative management of pheochromocytomas. Indian Journal of Urology 33:19–25. https://doi.org/10.4103/0970-1591.194781

Kamath AS, Singh K. Perioperative Management of Pheochromocytoma (2023). In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026 Jan. Available from: https://www.ncbi.nlm.nih.gov/books/NBK589634/

Xu K, Langenhuijsen JF, Viëtor CL, Feelders RA, Van Ginhoven TM, Elhassan YS, Bioletto F, Parasiliti-Caprino M, Zandee WT, Kruijff S, Backman S, Åkerström T, Pamporaki C, Bechmann N, Lussey-Lepoutre C, Canu L, Steenaard RV, Driessens N, Velema M, Dreijerink KMA, Engelsman AF, Timmers HJLM, De Laat JM (2024) PRAP study - partial versus radical adrenalectomy in hereditary pheochromocytomas. Eur J Endocrinol 191:345–353. https://doi.org/10.1093/ejendo/lvae108

Chittiboina P, Lonser RR (2015) Von Hippel-Lindau disease. Hssandb Clin Neurol 132:139–156.